
Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Report 2026
Global Outlook – By Type (Metered Dose Inhalers, Drug Powder Inhalers, Soft Mist Inhalers, Jet Nebulizers, Ultrasonic Nebulizers, Other Types), By Indication (Asthma, Chronic Obstructive Pulmonary Disease), By Application (Hospitals, Clinics, Home Care Settings, Research Institutions, Other Applications), By End User (Pediatric, Adult, Geriatric) – Market Size, Trends, Strategies, and Forecast to 2030
Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Overview
• Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices market size has reached to $47.56 billion in 2025 • Expected to grow to $62.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Growing Prevalence of Respiratory Diseases on COPD and Asthma Devices • Market Trend: Advancements In Smart Inhaler Technologies For Better Disease Control • North America was the largest region in 2025.Market Gains By 2030 – Top Opportunities By Segment
Market Gain identifies the most promising market opportunities by highlighting the segments or products expected to generate the highest incremental revenue growth over the next five years.
What Is Covered Under Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
Chronic obstructive pulmonary disease (COPD) and asthma devices refer to the medical devices used to manage and treat breathing and respiratory conditions. These devices help patients breathe more effectively, manage symptoms, and improve their quality of life. The main types of chronic obstructive pulmonary disease (COPD) and asthma devices are metered dose inhalers, drug powder inhalers, soft mist inhalers, jet nebulizers, ultrasonic nebulizers, and others. Metered Dose Inhalers are handheld devices that deliver medication in a precise dose as a spray or mist, typically used for treating conditions like COPD and asthma by inhaling the medication directly into the lungs. These devices are compact and portable, making them convenient for daily use by patients. The various indications include asthma and chronic obstructive pulmonary disease and are used in various applications such as hospitals, clinics, home care settings, research institutions, and others. The various end users include pediatric, adult, and geriatric.
What Is The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Size and Share 2026?
The chronic obstructive pulmonary disease (copd) and asthma devices market size has grown strongly in recent years. It will grow from $47.56 billion in 2025 to $50.3 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of asthma and COPD, increasing air pollution and smoking rates, growing use of inhalation therapy, expansion of respiratory care services, improved diagnosis of chronic respiratory diseases.What Is The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Growth Forecast?
The chronic obstructive pulmonary disease (copd) and asthma devices market size is expected to see strong growth in the next few years. It will grow to $62.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to aging population with higher respiratory risk, rising demand for home care respiratory devices, increasing awareness of early respiratory disease management, expansion of chronic disease management programs, growing access to respiratory care in emerging markets. Major trends in the forecast period include rising adoption of home-based respiratory care devices, increasing demand for portable and user-friendly inhalation devices, growing focus on long-term disease management solutions, expansion of device usage across pediatric and geriatric populations, increasing emphasis on treatment adherence and symptom control.
Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Segmentation
1) By Type: Metered Dose Inhalers, Drug Powder Inhalers, Soft Mist Inhalers, Jet Nebulizers, Ultrasonic Nebulizers, Other Types 2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease 3) By Application: Hospitals, Clinics, Home Care Settings, Research Institutions, Other Applications 4) By End User: Pediatric, Adult, Geriatric Subsegments: 1) By Metered Dose Inhalers: Conventional MDI, Breath-Actuated MDI 2) By Drug Powder Inhalers: Dry Powder Inhalers (DPI), Multi-Dose DPI 3) By Soft Mist Inhalers: Respimat Soft Mist Inhalers, Other Soft Mist Devices 4) By Jet Nebulizers: Pneumatic Nebulizers, Venturi-Type Nebulizers 5) By Ultrasonic Nebulizers: Tabletop Ultrasonic Nebulizers, Portable Ultrasonic Nebulizers 6) By Other Types: Nebulizer Accessories, Spacer Devices The top segments in the chronic obstructive pulmonary disease (copd) and asthma devices market will be: • Metered Dose Inhalers will reach $32.5 Billion by 2030. • Dry Powder Inhalers will reach $27.79 Billion by 2030. • Jet Nebulizers will reach $12.98 Billion by 2030. • Soft Mist Inhalers will reach $8.24 Billion by 2030. • Other Types will reach $7.38 Billion by 2030.What Is The Driver Of The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
The growing prevalence of respiratory diseases is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) and asthma devices market going forward. Respiratory diseases encompass many conditions affecting the lungs and respiratory systems, such as asthma, chronic obstructive pulmonary disease, pneumonia, and lung cancer, impacting breathing and overall respiratory function. The growing prevalence of respiratory diseases is due to increasing air pollution levels, changing climate patterns affecting allergens and pathogens, and lifestyle habits such as smoking that compromise respiratory health. COPD and asthma devices play a crucial role in the comprehensive management and treatment of respiratory diseases, supporting patients to achieve better respiratory health and enhance their overall well-being. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the number of COPD cases was expected to rise by 112 million, reaching a total of 592 million by 2050, which would represent 9.5% of the eligible population. Therefore, the growing prevalence of respiratory diseases drives the growth of the chronic obstructive pulmonary disease (COPD) and asthma devices markets.
Infographic Chart Showing Key Market Drivers Analysis And Restraints For Chronic Obstructive Pulmonary Disease (Copd) And Asthma Devices Market
The chart presents an impact analysis of key drivers and restraints, quantifying their relative influence on the market's growth rate and helping assess the balance between growth enablers and limiting factors. This chart offers a high-level perspective; the full report contains more detailed insights.
How Will The Drivers Impact Growth In The Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
• Rising Prevalence Of Chronic Respiratory Diseases (High) – During the forecast period, the rising prevalence of chronic respiratory diseases is expected to become a key growth driver for the chronic obstructive pulmonary disease (COPD) and asthma devices market by 2030. The increasing incidence of asthma, COPD, and other chronic pulmonary disorders is driving greater demand for effective respiratory treatment and disease management solutions. Growing exposure to environmental pollutants, smoking, occupational dust, and unhealthy lifestyles continues to elevate the global respiratory disease burden. This is encouraging healthcare providers to expand the use of inhalation therapies, nebulization systems, and respiratory monitoring devices to improve patient outcomes. Continuous efforts to strengthen respiratory care services and enhance long-term disease management are reinforcing sustained market expansion. • Increasing Geriatric Population (High) – During the forecast period, the increasing geriatric population is expected to emerge as a major factor driving the expansion of the chronic obstructive pulmonary disease (COPD) and asthma devices market by 2030. Aging populations are experiencing a higher incidence of respiratory impairment, creating greater demand for supportive respiratory therapies and routine disease management solutions. Older adults often require prolonged treatment, frequent clinical monitoring, and personalized respiratory care to maintain pulmonary function and reduce complications. Governments and healthcare organizations are expanding elderly healthcare services and chronic disease management programs, further supporting device utilization. • Growing Demand For Home-Based Respiratory Care (High) – During the forecast period, the growing demand for home-based respiratory care is expected to act as a key growth catalyst for the chronic obstructive pulmonary disease (COPD) and asthma devices market by 2030. The shift toward home healthcare is encouraging greater adoption of portable respiratory devices that enable convenient long-term treatment outside traditional clinical settings. Patients increasingly prefer home-based disease management to improve treatment adherence, reduce hospitalization, and support independent living. Advancements in portable respiratory technologies and remote patient management solutions are further enhancing accessibility and continuity of care.How Will The Restraints Impact Growth In The Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
• High Cost Of Respiratory Care Devices (High) – During the forecast period, the high cost of respiratory care devices is limiting the growth of the chronic obstructive pulmonary disease and asthma devices market, particularly in low-income and middle-income regions where affordability remains a major concern. Devices such as oxygen therapy equipment and long-term respiratory monitoring systems often involve significant purchase, maintenance, and replacement costs. Many patients face financial challenges in accessing advanced respiratory support devices without sufficient reimbursement coverage. Healthcare facilities with budget constraints may also limit procurement of respiratory care equipment, especially in resource-limited settings. The high overall cost burden reduces product accessibility and restricts wider adoption among economically disadvantaged populations. • Limited Awareness Regarding Early Respiratory Disease Management (High) – During the forecast period, the limited awareness regarding early respiratory disease management is restraining the growth of the chronic obstructive pulmonary disease and asthma devices market due to insufficient understanding of chronic respiratory disorders and their treatment options among patients. Many individuals remain undiagnosed or seek treatment only after symptoms become severe, reducing the timely adoption of respiratory care devices. In several developing regions, lack of education regarding preventive respiratory care and disease monitoring negatively affects device utilization. Limited awareness also contributes to poor adherence to prescribed respiratory therapies and monitoring practices. This challenge restricts market penetration and delays the adoption of respiratory management devices across underserved populations. • Stringent Regulatory And Compliance Requirements (High) – During the forecast period, the stringent regulatory and compliance requirements is hindering the growth of the chronic obstructive pulmonary disease and asthma devices market due to the extensive approval procedures associated with respiratory care equipment. Manufacturers must comply with strict quality, safety, and performance standards imposed by regulatory authorities before product commercialization. The regulatory process often increases operational costs and prolongs product launch timelines, particularly for small and medium-sized manufacturers. In addition, frequent updates in healthcare compliance standards create additional administrative and financial burdens for market participants. These regulatory complexities can delay market entry and limit the availability of respiratory care devices across multiple regions.Key Players In The Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market
Major companies operating in the chronic obstructive pulmonary disease (copd) and asthma devices market are AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Omron Corporation, Smiths Medical Inc., Cipla Ltd., Chiesi Farmaceutici SpA, Sunovion Pharmaceuticals Inc., Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd., 3M Health Care, Vyaire Medical Inc., Aerogen Ltd
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.

This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Trends and Insights
Major companies operating in the chronic obstructive pulmonary disease and asthma devices market are focusing on developing innovative solutions such as smart, sensor-enabled inhaler technologies to improve medication adherence, enable real-time symptom tracking, and support personalized respiratory disease management. Smart inhaler technologies involve integrating embedded sensors and digital connectivity features to capture inhalation data, monitor patient usage patterns, and deliver actionable insights to both patients and clinicians. For instance, in July 2023, Teva UK Ltd., a UK-based pharmaceutical company launched GoResp Digihaler, a digitally connected inhaler designed to record inhalation parameters, provide real-time feedback, and support improved disease control through data-driven patient engagement. The device helps enhance treatment outcomes by enabling remote monitoring, offering clinicians deeper visibility into patient adherence trends, and strengthening long-term disease management for individuals with chronic respiratory conditions.What Are Latest Mergers And Acquisitions In The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
In January 2025, Molex LLC, a US-based global electronics and connectivity solutions company, completed the acquisition of Vectura Group for an undisclosed amount. Through this acquisition, Molex aims to strengthen its healthcare and medical device capabilities by integrating Vectura’s advanced inhalation and drug-delivery technologies to expand its portfolio of connected, patient-centric respiratory solutions. Vectura Group is a UK-based pharmaceutical and medical device company specializing in inhaled drug-delivery systems for COPD, asthma, and other respiratory conditions.
Regional Outlook
North America was the largest region in the chronic obstructive pulmonary disease (COPD) and asthma devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, SpainWhat Defines the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
The chronic obstructive pulmonary disease (COPD) and asthma devices market consists of sales of spacer devices, peak flow meters, oxygen therapy equipment, pulse oximeters, and airway clearance devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.

This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
What Key Data and Analysis Are Included in the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Report 2026?
The chronic obstructive pulmonary disease (copd) and asthma devices market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (copd) and asthma devices industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $50.3 billion |
| Revenue Forecast In 2030 | $62.83 billion |
| Growth Rate | CAGR of 5.8% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Indication, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Omron Corporation, Smiths Medical Inc., Cipla Ltd., Chiesi Farmaceutici SpA, Sunovion Pharmaceuticals Inc., Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd., 3M Health Care, Vyaire Medical Inc., Aerogen Ltd |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
